Q-omics provides the consensus-scored TRIM46 profile across patient tissues and cancer cell-line models. TRIM46 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, TRIM46 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, TRIM46 RNA expression shows 18,067 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight ACC, HNSC, and UVM as cancer lineages where TRIM46 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRIM46 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRIM46 survival associations across molecular data types. TRIM46 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (6) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRIM46 RNA expression–survival associations across cancer types. High TRIM46 expression shows unfavorable associations in ACC, KIRC, UCEC, KIRP and STAD, but favorable associations in PAAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for TRIM46 RNA expression.
This table summarizes TRIM46 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 1. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for TRIM46. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRIM46 shows higher tumor expression in HNSC, COAD, LUAD, KIRC, LIHC and THCA. The HNSC box plot shows higher TRIM46 RNA expression in tumor versus normal tissue (log2 FC = +0.612, t-test p < 0.001).
This table shows molecular features associated with TRIM46 in patient tissues and cancer cell lines. In patient samples, TRIM46 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, TRIM46 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BLOOD_Leukemia.
